Background/Objectives: Ultra-low-dose radiotherapy (ULD-RT), an ultra-low-dose regimen delivering 4 Gy in two fractions, has emerged as a promising treatment for indolent ocular adnexal lymphoma (OAL), offering disease control with minimal toxicity. However, the clinical outcomes and safety profile of ULD-RT remain inconsistently reported across studies.Methods: We conducted a systematic review of peer-reviewed studies evaluating ULD-RT in patients with OAL, including prospective, retrospective, and comparative cohorts published between 2000 and 2025. A comprehensive search was performed in PubMed, Embase, and Scopus. Eligible studies reported clinical outcomes (e.g., response rates, local control, progression-free survival) and safety data (acute and late toxicities). Methodological quality was assessed using the Newcastle-Ottawa Scale (NOS).Results: Ten studies comprising 591 patients met the inclusion criteria. The overall response rate to ULD-RT ranged from 88% to 100%, with complete response rates of 50% to 95%. Local control rates ranged from 63% to 100%, and 2-year progression-free survival exceeded 85% in most studies. Importantly, no grade ≥ 3 toxicities were observed following the regimen of 4 Gy in two fractions. Acute toxicities occurred in up to 42% of patients, typically grade 1 dry eye or conjunctivitis. Late toxicities were uncommon (16–33%), with cataracts rarely requiring surgery. All included studies were rated as good quality (NOS score ≥ 7), indicating low risk of bias.Conclusions: ULD-RT is a highly effective and safe treatment modality for OAL, providing excellent local control with a favorable toxicity profile. These findings support the adoption of ULD-RT as a first-line radiotherapy strategy for indolent OAL. Future prospective trials with longer follow-up and standardized toxicity reporting are warranted to confirm and refine its clinical role.
**背景/目的：** 超低剂量放射治疗（ULD-RT）是一种超低剂量方案，以两次分割给予4 Gy总剂量，已成为治疗惰性眼附属器淋巴瘤（OAL）的一种前景广阔的方法，能在实现疾病控制的同时将毒性降至最低。然而，关于ULD-RT的临床疗效和安全性，不同研究报告的结果并不一致。 **方法：** 我们对评估ULD-RT用于OAL患者的同行评议研究进行了系统性综述，纳入了2000年至2025年间发表的前瞻性、回顾性及比较性队列研究。在PubMed、Embase和Scopus数据库进行了全面检索。符合条件的研究需报告临床疗效（如缓解率、局部控制率、无进展生存期）和安全性数据（急性和晚期毒性）。使用纽卡斯尔-渥太华量表（NOS）评估方法学质量。 **结果：** 共有10项研究符合纳入标准，涉及591名患者。ULD-RT的总体缓解率在88%至100%之间，完全缓解率在50%至95%之间。局部控制率在63%至100%之间，大多数研究中2年无进展生存率超过85%。重要的是，在两次分割4 Gy的方案后，未观察到≥3级的毒性反应。急性毒性发生率最高达42%，通常为1级干眼症或结膜炎。晚期毒性不常见（16–33%），白内障罕见需要手术。所有纳入的研究均被评为高质量（NOS评分≥7），表明偏倚风险较低。 **结论：** ULD-RT是治疗OAL的一种高效且安全的治疗方式，能提供优异的局部控制效果和良好的毒性特征。这些发现支持将ULD-RT作为惰性OAL的一线放射治疗策略。未来需要进行随访时间更长、毒性报告标准化的前瞻性试验，以确认并完善其临床作用。
肿瘤(癌症)患者之家